Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01062360 · ClinicalTrials.gov registry record · Phase 3
Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,016
- Enrollment target
NCT01062360 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 1,016 participants.
The verdict
NCT01062360, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,016 participants
- Enrollment target
Study Summary
The purpose of this study is compare efficacy and tolerability of a fixed combination, containing 500 mg Acetylsalicylic acid and 30 mg Pseudoephedrine, in comparison to its single components in patients with sore throat and nasal congestion.
Interventions
- DRUG Placebo
- DRUG Acetylsalicylic Acid (Aspirin, BAYE4465)
- DRUG Pseudoephedrine
- DRUG Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,016 participants |
| Start Date | 2005-12-23 |
| Est. Completion | 2007-05-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01062360
The ClinicalTrials.gov registry entry for NCT01062360 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,016 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01062360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01062360 about?
NCT01062360 is a clinical study titled "Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine". The purpose of this study is compare efficacy and tolerability of a fixed combination, containing 500 mg Acetylsalicylic acid and 30 mg Pseudoephedrine, in comparison to its single components in patients with sore throat and nasal congestion.
What is the current status of trial NCT01062360?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,016 participants. The study started on 2005-12-23. Estimated completion is 2007-05-14.
What interventions are being tested in trial NCT01062360?
The interventions under investigation include: Placebo (DRUG), Acetylsalicylic Acid (Aspirin, BAYE4465) (DRUG), Pseudoephedrine (DRUG), Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine (DRUG).
Who is sponsoring clinical trial NCT01062360?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.